|
|
 |
 |
TransPharma
Announces Successful Completion of a Phase 1b Clinical Trial of
ViaDor-GLP1 Agonist Indicated for the Treatment of Type II Diabetes
Lod, Israel, February 22, 2011 –
TransPharma Medical Ltd., a specialty pharmaceutical company focused on
the development and commercialization of drug products utilizing a
proprietary active transdermal drug delivery technology, announced
today the successful completion of a Phase 1b trial of ViaDor-GLP1
agonist, which is being developed for the treatment of diabetes
mellitus type II.
Read More
|
|
TransPharma
Changes
the Name of its Transdermal Drug Delivery System from ViaDerm to ViaDorTM
January 17, 2011 – TransPharma Medical Ltd., a specialty pharmaceutical
company focused on the development and commercialization of drug
products utilizing a proprietary active transdermal drug delivery
technology, announced today that it is replacing the name of its drug
delivery system from ViaDerm to ViaDorTM. The
new name better reflects
TransPharma's enhanced commercialization efforts and global
collaborations.
Read More
|
|
TransPharma
Announces Successful Results of
a Phase 1 Clinical Trial of ViaDerm-Calcitonin for the Treatment of
Musculoskeletal Disorders
January 11, 2011 – TransPharma Medical Ltd., a specialty pharmaceutical
company focused on the development and commercialization of drug
products utilizing a proprietary active transdermal drug delivery
technology, announced today successful results of a Phase I clinical
trial of its self-applied ViaDerm-Calcitonin product for the treatment
of musculoskeletal disorders such as osteoarthritis and musculoskeletal
pain.
Read More
|
|
TransPharma
Announces Successful Results of
a 4 week Phase 1 Clinical Trial of its New Self-applied ViaDerm System
for the Treatment of Osteoporosis
October 26, 2010 - TransPharma Medical Ltd., a specialty pharmaceutical
company focused on
the development and commercialization of drug products utilizing a
proprietary active transdermal drug delivery technology, announced
today successful results of a 4 week Phase 1 trial of its new
self-applied ViaDerm-hPTH(1-34) for the treatment of osteoporosis.
Read More
|
|
New
FORTEO(R) and EVISTA(R) Data to be Presented at Premiere Scientific
Meeting for Bone and Mineral Research
October 14, 2010 - Eli Lilly and Company
/quotes/comstock/13*!lly/quotes/nls/lly (LLY
37.76, +0.34, +0.91%) today announced that a total of 14 U.S. and
global studies involving its osteoporosis medications, FORTEO(R)
[teriparatide (rDNA origin) injection] and EVISTA(R) (raloxifene HCl
tablets), will be presented at the American Society for Bone and
Mineral Research (ASBMR) 2010 Annual Meeting from October 15-19 in
Toronto, ON, Canada.
Read More
|
|
|
|
TransPharma
Announces Successful Completion of Phase 1a Clinical Trial of
ViaDerm-GLP1 Agonist Indicated for the Treatment of Type II Diabetes
September
14, 2010 – TransPharma Medical Ltd., a specialty pharmaceutical company
focused on the development and commercialization of drug products
utilizing a proprietary active transdermal drug delivery technology,
announced today the successful completion of a Phase 1a trial of
ViaDerm-GLP1 agonist which is being developed for the treatment of
diabetes mellitus type II.
Read More
|
| |
|
| |
|
|
|
| |
For Earlier News
|
|
|
| |
© TransPharma Medical™ Ltd. All Rights Reserved.
updated Dec 2008
|
|
